Search results: (10000)
News New Natural Method for Prevention and Treatment of House Dust Mite Allergy
House dust mites are among the most common triggers of respiratory allergies. Until now, therapy has primarily focused on alleviating allergy symptoms. The aim of the new natural-based method is to eliminate the etiology of the issues, specifically the house dust mites themselves.
News Diagnosis, Treatment, and Outcomes Achieved in Patients with Non-Small-Cell Lung Cancer in Central Europe
In June 2020, the journal Radiology and Oncology published the results of an analysis of data from patients with stage III non-small-cell lung cancer (NSCLC) from a Central European registry. A large team led by Czech experts focused on the diagnostic and therapeutic procedures used and the treatment results achieved in real-world practice.
News Can We Reach Brain Metastases of Lung Cancer with Anti-EGFR Targeted Therapy?
Information on the penetration of epidermal growth factor receptor tyrosine kinase inhibitors (anti-EGFR TKIs) through the blood-brain barrier primarily comes from preclinical testing. In clinical studies, its effectiveness in patients with brain metastases can be an indicator of its penetration. However, a truly robust analysis is lacking. Until one is available, we can preliminarily evaluate the available data.
News New Alternative in the Treatment of Diffuse Large B-cell Lymphoma
For patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) who are not suitable candidates for autologous stem cell transplantation, a wide range of treatment regimens is available. Recently, the addition of polatuzumab vedotin to rituximab and bendamustine therapy has shown promising efficacy in both registration studies and real-world clinical practice.
News ASH 2020: Efficacy and Safety of Emicizumab in Long-term Follow-up
At the virtual meeting of the American Society of Hematology (ASH) in December 2020, the latest data concerning the long-term follow-up of participants in the HAVEN 1−4 clinical trials with emicizumab were published.
News ASH 2020: Two Real-World Perspectives on Experiences with Emicizumab Prophylaxis
Data presented at the ASH 2020 congress bring interesting insights regarding the administration of emicizumab in real clinical practice. It provides comprehensive information on the relatively high number of individuals treated with emicizumab in relation to persistence on treatment and adherence to it. Data from the EUHASS registry confirms the good safety profile of this treatment even in regular clinical practice across Europe.
News Older patients with CLL and comorbidities: an option for treatment with immunotherapy without chemotherapy?
Is it time to treat chronic lymphocytic leukemia (CLL) without chemotherapy? The authors of a recently published article in the Expert Review of Hematology journal attempted to answer this question.
News Efficacy and Safety of Preservative-Free Latanoprost in the Treatment of Open-Angle Glaucoma and Elevated Intraocular Pressure – Results of a Meta-Analysis
Many eye drops for the treatment of glaucoma still contain preservatives today. However, these can cause eye irritation, so non-preservative formulations should be preferred. The following meta-analysis compared the efficacy and safety of antiglaucoma medications with and without preservatives.
News Trifluridine/Tipiracil in the 3rd Line Treatment of mCRC − Case Study
The following case study describes the treatment of a patient with metastatic colorectal cancer (mCRC) and the benefits of trifluridine/tipiracil within the therapeutic algorithm.
News Does olaparib improve overall survival in patients with recurrent ovarian cancer and BRCA mutation?
Olaparib, a poly(ADP-ribose) polymerase (PARP) enzyme inhibitor, in tablet form is indicated, among other things, for the maintenance treatment of adult patients with platinum-sensitive recurrent high-grade epithelial ovarian, fallopian tube, or primary peritoneal cancer who respond (complete or partial response) to platinum-based chemotherapy. Its efficacy in this indication in terms of prolonging progression-free survival and overall survival was addressed by the phase III study presented below.
News International Recommendations for COVID-19 Vaccination in People with Bleeding Disorders
At the end of December 2020, international guidelines for COVID-19 vaccination in people with bleeding disorders were published on the World Federation of Hemophilia (WFH) website. We present a basic summary of 13 points of this consensus. The original English version is available via the web link cited at the end of the article.
News COVID-19: Specifics of Care for Individuals with Congenital Bleeding Disorders
The COVID-19 pandemic has significantly impacted nearly all medical fields. Alongside direct care focused on seriously ill patients, the pandemic also affects the care of chronic patients, including those with hemophilia. However, there is currently not much specific data available regarding experiences with COVID-19 in patients with hemophilia. The specifics of congenital bleeding disorders, especially in relation to the severe course of COVID-19, are discussed by Italian authors in their article published in the journal Seminars in Thrombosis and Hemostasis.
News Recommend Erdostein for children when treating with amoxicillin – symptoms of cough improve in almost 50% of cases within 3 days
Acute respiratory infections are usually treated empirically in primary care as the causative agent is not known. Amoxicillin is among the most commonly chosen antibiotics. Erdostein is a suitable addition to this antibiotic treatment for several reasons.
News Is the efficacy of bisoprolol in secondary prevention of acute myocardial infarction in patients after percutaneous coronary intervention comparable to carvedilol?
Beta-blockers (BB) are recommended for all patients after percutaneous coronary intervention (PCI) as part of secondary prevention of acute myocardial infarction (AMI). The study presented below compared the efficacy of carvedilol – a vasodilating beta-blocker, whose benefit in this indication was confirmed by a randomized clinical trial – with the effect of bisoprolol.
News How to Care for Dialysis Patients in the Times of COVID-19
More than 2 million people worldwide undergo maintenance hemodialysis in outpatient centers. Effective prevention of the spread of infection caused by the SARS-CoV-2 coronavirus within the care provided by hemodialysis centers is essential for the smooth provision of dialysis to patients with end-stage renal disease. The following work from experts in Boston is based on their experiences as well as recommendations from the American Society of Nephrology (ASN) and the Centers for Disease Control and Prevention (CDC).